Development of unstable resistance to diminazene aceturate in *Babesia bovis*

Bumduuren Tuvshintulga, Thillaiampalam Sivakumar, Naoaki Yokoyama, Ikuo Igarashi*

National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada-cho, Obihiro, Hokkaido, 080-8555, Japan

ARTICLE INFO

Keywords:

Babesia bovis

Unstable drug resistance

Diminazene aceturate

In vitro

ABSTRACT

Diminazene aceturate (DA) is commonly used in the treatment of bovine babesiosis caused by *Babesia bovis*. In this study, we attempted to develop resistance in *B. bovis* *in vitro* to DA and clofazimine (CF, a novel antibabesial agent) using short- and long-term drug pressures. In the short term, we found that 6.7 ± 2 ($0.54 \pm 0.16 \mu\text{M}$), 12.9 ± 8.6 ($1.05 \pm 0.7 \mu\text{M}$), and 14 ± 5.9 ($1.14 \pm 0.48 \mu\text{M}$)-fold increases in the half-maximal inhibitory concentration (IC_{50}) of DA were demonstrated on *B. bovis* cultivated with $0.04 \mu\text{M}$ of DA pressure for 4, 8, and 12 days, respectively, as compared to that on parental culture ($0.08 \pm 0.0065 \mu\text{M}$) before drug pressure was initiated. However, in *B. bovis* cultivated with $0.04 \mu\text{M}$ of DA pressure after 16 days, the parasites could not tolerate $0.8 \mu\text{M}$ of DA. In the long term, 7.6 ± 3.5 -, 20.5 ± 0.1 -, and 26.8 ± 5.5 -fold increases in the IC_{50} of DA were demonstrated on parasites from subcultures at days 8, 3, and 5 post-cultivation, respectively, in a drug-free medium, where these subcultures were obtained from *B. bovis* cultivated with DA pressure with changing doses for 30, 60, and 90 days, respectively. However, the second and third times, no increase was demonstrated on *B. bovis* from these subcultures at days 15 and 30 post-cultivation in a drug-free medium. In addition, in *B. bovis* cultivated with drug pressure after 90 days, the parasites tolerate up to $0.64 \mu\text{M}$ DA. All findings demonstrated that DA resistance in *B. bovis* is unstable and lost within 15 days of drug withdrawal. However, treatment with subtherapeutic doses of DA in cattle might result in the development of resistance in *B. bovis*, which may not even respond to subsequent treatments with high doses of DA. Thus, if the bovine babesiosis caused by *B. bovis* is unresponsive to DA, treatment with other antibabesial agents might be recommended.

1. Introduction

The emergence of drug resistance in pathogens which include bacteria, protozoa, and fungi is a major challenge for the successful treatment of infectious diseases (Fairlamb et al., 2016; Yoshida et al., 2017). During last few decades, protozoan parasites have developed resistance to several antiprotozoal agents through various mechanisms, such as genetic changes in the target sites, the reduced uptake and increased efflux of drugs, and metabolic regulations (Fairlamb et al., 2016; Lemieux et al., 2016). The emergence of drug-resistant parasites has serious implications for treating clinical cases, leading to increased morbidity and mortality (Fairlamb et al., 2016). For instance, the emergence of *P. falciparum* strains resistant to almost all of the anti-malarial agents has severely undermined malaria control programs (Corey et al., 2016).

The development of drug resistance in *Babesia* species, which are intraerythrocytic apicomplexan parasites, has been well documented (Hwang et al., 2010; Krause et al., 2008; Lemieux et al., 2016; Matsuu et al., 2006). A combination therapy of atovaquone with azithromycin is recommended for the treatment of human babesiosis caused by

Babesia microti (Krause et al., 2000), but *B. microti* strains resistant to both drugs have emerged recently (Krause et al., 2008; Lemieux et al., 2016; Wormser et al., 2010). In addition, a previous study found that treatment with atovaquone induces the development of resistance in *Babesia gibsoni* in dogs (Matsuu et al., 2006). The possible mechanism of atovaquone resistance is suggested to be point mutations that result in amino acid substitution in cytochrome *b*, which is the molecular target of atovaquone (Lemieux et al., 2016; Matsuu et al., 2006).

Diminazene aceturate (DA) is an antibabesial agent commonly used for the treatment of animal babesiosis, which is caused by a species of *Babesia* and has worldwide distribution (Bock et al., 2004; Mosqueda et al., 2012). Although different species of *Babesia* infect cattle, only three *Babesia* species including *B. bovis*, *B. bigemina*, and *B. divergens* are known to cause severe clinical babesiosis (Bock et al., 2004). In particular, *B. bovis* causes the most severe form of bovine babesiosis, as the parasite-infected erythrocytes adhere to the endothelial cells in the capillaries in internal organs, such as the brain and lungs, leading to neurological and respiratory signs (Everitt et al., 1986). Control strategies against *B. bovis* include tick control, vaccination, and chemotherapy (Bock et al., 2004; Mosqueda et al., 2012). Tick-control

* Corresponding author.

E-mail address: igarcpmi@obihiro.ac.jp (I. Igarashi).<https://doi.org/10.1016/j.ijpddr.2019.02.001>

Received 26 December 2018; Received in revised form 7 February 2019; Accepted 12 February 2019

Available online 13 February 2019

2211-3207/ © 2019 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

strategies are often ineffective because of the development of acaricide resistance (Kunz and Kemp, 1994). Although live vaccines are used in several endemic countries, the wide use of such a vaccine is prevented by various factors, such as the risk of contamination with other blood pathogens, lack of protection due to strain variations, and time-consuming production procedures (Bock et al., 2004; Brown et al., 2006). Therefore, chemotherapy including DA is vital for minimizing the economic damage caused by *Babesia* parasites, including *B. bovis*. Unfortunately, however, recent studies have suggested the possible development of DA resistance in *Babesia* parasites (Hwang et al., 2010; Yamasaki et al., 2017). For instance, *in vitro* treatment with low to high doses of DA resulted in the development of DA-resistant *B. gibsoni* (Hwang et al., 2010). In addition, the low efficacy of DA against *B. bovis* in cattle has sometimes been documented, suggesting the possibility of the emergence of drug-resistant *B. bovis* in these cases (Mosqueda et al., 2012; Vial and Gorenflot, 2006). However, the development of DA-resistant *B. bovis* has never been investigated. Therefore, in the present study, we investigated whether continuous drug pressure could induce the emergence of DA-resistance in *B. bovis in vitro*. In parallel, we also investigated whether such drug pressure could result in *B. bovis* strains resistant to clofazimine (CF), an antibiotic that has recently been characterized as a potent antibabesial agent.

2. Materials and methods

2.1. Parasite and cultivation

The Texas strain of *B. bovis* was maintained in fresh cattle erythrocytes (from a mature Holstein cow) and serum-free GIT culture medium supplemented with $1 \times$ antibiotic-antimycotic solution containing 100 U/ml of penicillin G, 100 µg/ml of streptomycin, and 0.25 µg/ml of amphotericin B, as previously described (Bork et al., 2005). Cultures were maintained in a multi-gas water-jacketed incubator in an atmosphere of 5% O₂ and 5% CO₂ at 37 °C. The culture medium was changed every day. All chemicals were purchased from Sigma-Aldrich (Tokyo, Japan).

2.2. Drugs

DA was purchased from Ciba-Geigy Japan Ltd. (Tokyo, Japan). CF was purchased from Sigma-Aldrich (Tokyo, Japan). DA and CF were dissolved in Milli-Q water (MQW) and dimethyl sulfoxide (DMSO), respectively, to prepare 10 mM stocks.

2.3. Determination of the IC₅₀s of DA and CF

The half-maximal inhibitory concentrations (IC₅₀s) of DA and CF were calculated on *in vitro* growth of *B. bovis* in serum-free GIT culture media using a fluorescence-based growth-inhibition assay as previously described (Rizk et al., 2015). Briefly, 97.5 µL of 0.01, 0.1, 0.5, 2.5, 5, 10, and 20 µM of DA and 0.025, 0.25, 1.25, 6.25, 12.5, 25, and 50 µM of CF prepared in a culture medium was added in triplicate to a 96-well culture plate. To examine whether these solvents affect the growth of parasites, media containing 0.2% MQW and 0.5% DMSO (calculated based on their concentration in the highest dose of DA and CF, respectively) were also added in triplicate as untreated controls. When the percentage of parasitized erythrocytes (%PE) was calculated to be over 4% in previously maintained *B. bovis in vitro* cultures, the 4% PE were further diluted with fresh erythrocytes to achieve 1% PE, and then 2.5 µL of the 1% PE was added to each well. These 100 µL of cultures with 2.5% hematocrit concentration (HTC) and 1% initial PE were incubated as described in section 2.1 for 3 days without changing media. On day 3, 100 µL lysis buffer containing $2 \times$ SYBR Green I (Lonza Rockland, Inc., Rockland, ME, USA) was added to each well, and then incubated at room temperature in the dark for 6 h. The fluorescence values were determined at 485 nm excitation and 518 nm emission

wavelengths. Fluorescence values were corrected for background signals, converted to growth rates relative to untreated controls, and then the IC₅₀s of DA and CF were calculated by a curve-fitting method. The calculated IC₅₀s of DA and CF against *B. bovis* were 0.08 ± 0.0065 µM and 1.55 ± 0.045 µM, respectively. These IC₅₀s of drugs were compared with the IC₅₀s of DA and CF on parasites subjected to drug pressure, as described in sections 2.4 and 2.5.

2.4. Short-term DA and CF pressure with $\frac{1}{2} \times$ IC₅₀ doses

B. bovis in vitro cultures were subjected to DA and CF pressure for 24 days (Suppl. Fig. 1). Briefly, in 24-well culture plates, 100 µL of bovine erythrocytes containing 1% PE was added to each well together with 900 µL of culture medium (10% HTC) containing $\frac{1}{2} \times$ IC₅₀ doses of DA (0.04 µM) and CF (0.8 µM) and incubated as described in section 2.1. The culture medium was replaced every 24 h with fresh medium containing 0.04 µM of DA or 0.8 µM of CF. In addition, 0.2% MQW and 0.5% DMSO solvents of DA and CF, respectively, were used as respective untreated controls. On days 4, 8, 12, and 16 (every 4 days), Giemsa-stained erythrocyte smears were prepared to calculate the %PE, and then parasite-infected erythrocytes from each culture were used to prepare subcultures with 1% initial PE. The drug pressure with the $\frac{1}{2} \times$ IC₅₀ dose was continued on the subcultures (1% initial PE) prepared on days 0, 4, 8, and 12, while the subcultures (1% or 4% initial PE) prepared from MQW-, DA-, DMSO-, and CF-treated cultures on day 16 were treated with $10 \times$ IC₅₀ doses of DA (0.8 µM) and CF (16 µM), respectively, for the next 8 days. On days 4, 8, and 12, parasites from the treated cultures were also used to determine the IC₅₀s of both DA and CF in order to assess the potential development of drug resistance in *B. bovis*. The IC₅₀s of DA and CF on *B. bovis* cultivated with drug pressure were calculated, essentially as described in section 2.3, using the fluorescence-based method. These IC₅₀s were then compared with the IC₅₀s of DA and CF as determined on previously untreated *B. bovis* cultures in section 2.3. All experiments were repeated 4 times.

2.5. Long-term DA and CF pressure with changing doses

Similar to short-term drug pressure, the cultures were initiated with 1% PE and 10% HTC, and the culture medium containing DA and CF was replaced every day (Suppl. Fig. 2). However, instead of preparing subcultures, fresh erythrocytes were added to the cultures, based on the HTC reductions, to maintain 10% HTC throughout the experiment. The drug pressure was initiated with a $\frac{1}{2} \times$ IC₅₀ dose for DA (0.04 µM) or CF (0.8 µM). Monitoring of the %PE was performed by using Giemsa-stained erythrocyte smears. The drug doses were increased or decreased based on the levels of %PE. Subcultures were prepared and maintained in a drug-free medium after 30, 60, and 90 days of drug pressure. When over 4% PE were calculated in these subcultures (on days 8, 3, and 5 for subcultures prepared from *B. bovis* cultivated with drug pressure for 30, 60, and 90 days, respectively), parasites from these subcultures were used to determine the IC₅₀s of both DA and CF for the first time. The second and third times, the IC₅₀s of drugs on subcultures maintained in a drug-free medium were determined on days 15 and 30, respectively. The experiment was repeated twice.

2.6. DA and CF pressure with constant and increasing doses

After 90 days of drug pressure, as described in section 2.5, the cultures were treated with IC₅₀ doses of DA and CF for another four days (Suppl. Fig. 2). After the %PE was calculated at day 94, subcultures (1% initial PE and 10% HTC) were prepared and subjected to treatment with the IC₅₀ doses of DA and CF for three days. After this 3-day treatment, subcultures were prepared at day 97 from these cultures and treated with $2 \times$ IC₅₀ doses of DA (0.16 µM) and CF (3.2 µM) for 4 days. Subsequent subcultures prepared from the DA-treated cultures on days 101, 105, 109, 113, 117, and 121 were each treated for 4 days

with $4 \times$, $5 \times$, $6 \times$, $7 \times$, $8 \times$, and $9 \times$ IC_{50} doses of DA (0.32, 0.4, 0.48, 0.56, 0.64, and 0.72 μ M, respectively). On the other hand, subcultures from CF-treated cultures prepared on days 97, 101, 105, 109, 113, and 117 were each treated for 4 days with a $2 \times$ IC_{50} dose of CF (3.2 μ M), as the %PE in treated cultures did not increase. The experiment was repeated twice.

2.7. Statistical analysis

An unpaired Student's *t*-test with two-tailed method in Microsoft Excel (2016) was used to calculate the *P* values. A *P* value < 0.05 was considered to indicate significant differences between the IC_{50} s of drugs or the %PE in drug-treated cultures and their untreated controls.

3. Results

3.1. Short-term DA and CF pressure with $\frac{1}{2} \times IC_{50}$ doses

As described in section 2.3, the calculated IC_{50} s of DA and CF on *B. bovis* in the parental culture were $0.08 \pm 0.0065 \mu$ M and $1.55 \pm 0.045 \mu$ M, respectively. We used $\frac{1}{2} \times IC_{50}$ of DA (0.04 μ M) and CF (0.8 μ M) as drug pressure for 16 days because *B. bovis* was able to tolerate a $\frac{1}{2} \times IC_{50}$ dose of the drugs (Suppl. Fig. 3A and B). On every 4th day of cultures, the IC_{50} s of DA were 0.54 ± 0.16 , 1.05 ± 0.7 , and $1.14 \pm 0.48 \mu$ M in *B. bovis* cultivated with 0.04 μ M DA pressure for 4, 8, and 12 days, respectively, demonstrating that the IC_{50} of DA on the parental culture ($0.08 \pm 0.0065 \mu$ M) was increased by 6.7 ± 2 -, 12.9 ± 8.6 -, and 14 ± 5.9 -folds, respectively (Fig. 1A, DA-line in the development of resistance). In the case of the untreated control, the determined IC_{50} s of DA were similar against parasites from

parental and 0.2% MQW-treated cultures (Fig. 1A, MQW-line in the development of resistance). On day 16, 0.04 μ M DA- and MQW-treated parasites in subcultures (1% or 4% initial PE) were subjected to treatment with $10 \times IC_{50}$ dose (0.8 μ M) of DA for 8 days. Although the %PE in subcultures was significantly higher than that in the untreated MQW control during treatment with 0.8 μ M DA, parasites cultivated with 0.04 μ M DA pressure could not tolerate the $10 \times IC_{50}$ dose (0.8 μ M) of DA for more than 8 days (Fig. 1B). On the other hand, the IC_{50} of CF ($1.55 \pm 0.045 \mu$ M) increase of less than 5-fold was demonstrated against parasites cultivated with CF pressure for 4, 8, and 12 days and the untreated DMSO control as well (Fig. 1A, DMSO- and CF-lines in the development of drug resistance). Additionally, in *B. bovis* cultivated with CF pressure with a $\frac{1}{2} \times IC_{50}$ dose of CF after 16 days, the parasites died on day 4 after treatment with CF at a $10 \times IC_{50}$ dose, as this result was similar to that of DMSO control (Fig. 1C). In addition, we found that parasites cultivated with CF and DA pressures were still sensitive to DA and CF, respectively, and the determined IC_{50} s of DA and CF were comparable to those against their untreated DMSO and MQW controls (Fig. 1A, DMSO-, CF-, MQW-, and DA-lines in cross-resistance).

3.2. Long-term DA and CF pressure with changing doses

After 30, 60, and 90 days of drug pressure with changing doses, three subcultures were obtained in drug-free medium (Suppl. Fig. 4A and B). Parasites from these 3 subcultures were then used to determine the IC_{50} s of drugs for the first time on days 8, 3, and 5, and then for a second and third time on days 15 and 30, respectively (Suppl. Fig. 5A, B, and C). The first time, 7.6 ± 3.5 -, 20.5 ± 0.1 -, and 26.8 ± 5.5 -fold higher IC_{50} s of DA against *B. bovis* sourced from these 3 subcultures at 8, 3, and 5 post-cultivation in drug-free medium, respectively, as





Fig. 1. Short-term DA and CF pressure with a $\frac{1}{2} \times IC_{50}$ dose. A) The IC_{50} s of drugs calculated after 4, 8, and 12 days of drug pressure are illustrated as fold changes compared with the IC_{50} s of drugs determined before the initiation of drug pressure. Note that the IC_{50} of DA on *B. bovis* previously subjected to DA pressure significantly increased, while the IC_{50} of CF on *B. bovis* cultivated with CF pressure increased only slightly. Also note that the IC_{50} s of CF and DA on *B. bovis* that had been subjected to DA and CF drug pressure, respectively, were comparable to the IC_{50} s of drugs on the parental line and those against their untreated controls. B) Monitoring of %PE in a $10 \times IC_{50}$ dose of DA (0.8 μ M)-treated culture initiated with *B. bovis* that had been subjected to 16 days of drug pressure with DA. Note that *B. bovis* cultivated with drug pressure grew with high parasitemia as compared with that in the untreated MQW control. C) Monitoring of %PE in a $10 \times IC_{50}$ dose of CF (16 μ M)-treated culture initiated with *B. bovis* that had been subjected to 16 days of drug pressure with CF. Note that *B. bovis* cultivated with drug pressure and the untreated DMSO control lines grew similarly with low parasitemia.



compared to the IC₅₀ of DA ($0.08 \pm 0.0065 \mu\text{M}$) determined before the drug pressure was initiated (Fig. 2A, DA-line in the development of drug resistance). However, the second and third times, no increase in the IC₅₀ of DA was demonstrated on parasites from subcultures at days 15 and 30 post-cultivation in drug-free medium (Suppl. Fig. 6). In contrast, all IC₅₀s of CF determined on subcultures obtained from *B. bovis* cultivated with 30, 60, and 90 days of CF pressure were comparable to the IC₅₀ of CF determined before the initiation of drug pressure, except for the first IC₅₀ of CF (increased 6-fold) on the subcultures obtained from parasites cultivated with 90 days of CF pressure (Fig. 2A, CF-line in the development of drug resistance, and Suppl. Fig. 6). In addition, all IC₅₀s of DA and CF on subculture-obtained parasites cultivated with CF and DA over the long term, respectively, were similar to the IC₅₀s of drugs determined on parental cultures before the initiation of drug pressure, further confirming that unstable resistance induced by DA is specific to DA (Fig. 2A, CF- and DA-lines in cross-resistance, and Suppl. Fig. 6).

3.3. DA and CF pressure with constant and increasing doses

After 90 days of drug pressure, we tested the effect of increasing doses of DA and CF on the development of drug resistance. After treating with fixed doses for 4 days, subcultures were prepared, and treatment was continued for several days with increased doses of DA and CF. The drug doses were increased until the parasites died. The parasites grew in an $8 \times \text{IC}_{50}$ dose ($0.64 \mu\text{M}$) of DA, but all parasites died when treated with $9 \times \text{IC}_{50}$ dose ($0.72 \mu\text{M}$) of DA (Fig. 2B). In contrast, all CF-treated parasites died when treated with CF at $2 \times \text{IC}_{50}$ dose ($3.2 \mu\text{M}$) at day 121 (Fig. 2C).

4. Discussion

The emergence of drug-resistant parasites is one stumbling block for the effective treatment of babesiosis (Krause et al., 2008; Matsui et al., 2006; Vial and Gorenflot, 2006; Wormser et al., 2010; Yeruham et al., 1985). In general, parasite lines are considered to be resistant to a given drug if the IC₅₀ of the drug increased by more than 10-fold as compared to the parent line (Nzila and Mwai, 2010). In the present study, we also found that a more than 10-fold increase in the IC₅₀ of DA was determined on *B. bovis* cultivated with a $\frac{1}{2} \times \text{IC}_{50}$ dose ($0.04 \mu\text{M}$) of DA for 8 and 12 days (Fig. 1A). Therefore, the present findings suggest that short-term pressure with DA induces resistance in *B. bovis*. However, when we attempted to expose drug resistance from the culture with 16 days of pressure using a treatment with a $10 \times \text{IC}_{50}$ dose ($0.8 \mu\text{M}$), parasites did not grow for more than 8 days (Fig. 1B). These observations suggest that DA-resistant parasites emerging after short-term drug pressure cannot tolerate high doses of DA. On the other hand, no more than a 5-fold increase in the IC₅₀ of CF was demonstrated on *B. bovis* cultivated with a $\frac{1}{2} \times \text{IC}_{50}$ dose ($0.8 \mu\text{M}$) of CF. These slight changes in the IC₅₀ of drugs may not indicate the development of resistance, as the fold changes were less than 10 (< 5 -fold) (Corey et al., 2016; Nzila and Mwai, 2010). Therefore, this result suggests that the development of resistance to CF in *B. bovis* is unlikely with a short-term treatment. A previous study found a low efficacy of antibabesial agents, including clindamycin, doxycycline, and pentamidine, against DA-resistant *B. gibsoni* (Hwang et al., 2010). In addition, our previous study found that both DA and CF may bind AT-rich DNA regions in mitochondrial and plastid (apicoplast) genomes of *B. bovis* (Tuvshintulga et al., 2017). However, in the present study, DA-resistant *B. bovis* was not resistant to CF, indicating that resistance in *B. bovis* induced by DA pressure is

Fig. 2. A long-term drug pressure with changing doses of DA or CF. A) *B. bovis* cultures were subjected to 30, 60, and 90 days of DA and CF drug pressure with doses determined based on the parasitemia dynamics; they were then maintained in drug-free medium. Parasites from the cultures maintained in a drug-free medium were then used to determine the IC₅₀s of drugs for the first time on days 8, 3, and 5, and then for second and third times on days 15 and 30, respectively. The fold changes in the IC₅₀s of drugs as compared with the IC₅₀s of drugs on the parental lines were plotted. Note that the first IC₅₀s of DA on *B. bovis* that had been subjected to drug pressure were significantly higher as compared to the IC₅₀s of DA on the parental line, and that second and third determinations of the IC₅₀s of DA were comparable to the IC₅₀s of DA on the parental line. Also note that fold changes in the IC₅₀s of CF on *B. bovis* cultivated with CF drug pressure were less pronounced. Additionally, the IC₅₀s of DA and CF on *B. bovis* that had been subjected to CF and DA drug pressure, respectively, were comparable to those against the parental line. B) Monitoring of %PE in culture treated with constant as well as increasing doses of DA, showing *B. bovis* was able to grow in an $8 \times \text{IC}_{50}$ dose of DA ($0.64 \mu\text{M}$). C) Monitoring of %PE in culture treated with constant as well as increasing doses of DA, showing *B. bovis* was able to grow only $2 \times \text{IC}_{50}$ of CF ($3.2 \mu\text{M}$).

specific to DA.

Next, the stability and tolerable dose of drug-resistant *B. bovis* in a drug-free medium were investigated after long-term drug pressure with changing doses based on the levels of %PE. We found that after 30, 60, and 90 days of drug pressure, approximately 7.6, 20, and 26-fold increases, respectively, in the IC₅₀ of DA were demonstrated on *B. bovis* in subcultures at days 8, 3, and 5 post-cultivation in a drug-free medium, respectively, suggesting that DA resistance becomes more prominent with the duration of drug pressure. On the other hand, a previous study interpreted a possibility that a biphasic dose-response curve of drug indicates presence of two populations in a culture line such as drug-resistant and -sensitive parasites, whereas a monophasic dose-response curve indicates a single population (Nzila and Mwai, 2010). In the present study, we observed the monophasic dose-response curve of DA against parasites from parental culture and 0.04 µM DA-treated cultures in the short-term drug pressure, but the biphasic dose response curve of DA was only observed against *B. bovis* cultivated in a drug-free medium after the long-term drug pressure (Suppl. Fig. 7A and B). These results indicate that the DA resistance induced by drug pressure might be unstable when cultivated in a drug-free medium. Moreover, in the long-term drug pressure, no increase was demonstrated again on these parasites in a drug-free medium on days 15 and 30 post-cultivation, confirming that DA-resistant parasite is lost when cultivated in a drug-free medium for 15 days. The findings of present study collectively indicate that drug pressure with DA results in the development of unstable resistance in *B. bovis*. In previous studies, resistance to DA has been reported in *Trypanosoma* and *B. gibsoni* (de Koning et al., 2004; Hwang et al., 2010). The uptake of DA in *Trypanosoma brucei* and *T. equiperdium* is mediated by an adenosine transporter known as P2, which is encoded by the *TbAT1* and *TevAT1* genes, respectively (de Koning et al., 2004; Witola et al., 2005). It has been proposed that the loss of activity of the P2 transporter in DA-resistant strains results in the low uptake of DA into *Trypanosoma*, leading to the reduced efficacy of DA (de Koning et al., 2004). In addition, upregulated mRNA expression of the *TeDR40* gene contributes to increased resistance of *T. evansi* to DA (Witola et al., 2005). In a recent study, the reduced uptake of DA was observed in *B. gibsoni* resistant to DA, similar to DA-resistant *Trypanosoma* (Yamasaki et al., 2017). The same study found that the reduced uptake of DA is unlikely due to the loss of P2 transporter activity. Although the genes linked to DA-resistant *Babesia* are unknown, our previous study revealed that *B. bovis* mitochondrial (*cob* and *cox3*) and apicoplast (*tufA* and *clpC*) genes were upregulated during treatment with DA, while these genes were downregulated in CF-treated *B. bovis* (Tuvshintulga et al., 2017). This may imply that temporally upregulated apicoplast and mitochondrial genes contribute to developing the unstable resistance in *B. bovis* to DA. Nevertheless, future investigation is necessary to clarify this assumption by using a quantitative analysis of mRNA in *B. bovis* withdrawal DA pressure. Although the mechanism of DA resistance in *B. bovis* is unclear, the present findings indicate that such mechanisms operate only during drug pressure, and parasites lose their resistance within 15 days of drug withdrawal. Therefore, the acquisition of DA-resistant *B. bovis* from cattle and its subsequent transmission to other cattle by tick vectors are highly unlikely. However, the unstable resistance of DA might potentially implicate the outcome of DA treatment in cattle with clinical babesiosis. Following intramuscular administration of a standard dose of DA (3.5 mg/kg dose), the half dose of this compound is eliminated from cattle's bodies within 7 days (Kellner et al., 1985). However, DA residue can still be found in urine and feces for more than 20 days. Therefore, if DA is administered at low doses, which are not sufficient to kill all parasites, surviving *B. bovis* in cattle might develop DA resistance, leading to treatment failures, even if cattle are subsequently treated with high doses of DA. Previously reported DA treatment failures in cattle with babesiosis caused by *B. bovis* might have been associated with the unstable development of DA resistance, although the details on doses of DA used in such cases are unknown (Mosqueda et al., 2012; Vial and Gorenflot, 2006).

In summary, the present study found that DA treatment results in the development of resistance in *B. bovis* *in vitro*. When the doses of DA were increased gradually, *B. bovis* was able to tolerate up to an 8-fold dose, as compared to the IC₅₀ dose of DA determined before the drug pressure. Resistance was stable for less than 15 days of drug withdrawal, indicating that DA resistance in *B. bovis* is unstable. However, unstable resistance to DA might lead to DA treatment failures in cattle with clinical babesiosis caused by *B. bovis*. On the other hand, our findings showed that the development of resistance to CF is unlikely in *B. bovis*. We also found that DA-resistant *B. bovis* is still sensitive to CF, suggesting that resistance is specific to DA only. Thus, in situations where bovine babesiosis caused by *B. bovis* is unresponsive to DA, treatment with alternative antibabesial agents, such as CF, might be recommended.

Authors' contributions

All authors conceived the present study. B.T. conducted all experiments in the present study and wrote the first draft of the manuscript, and all authors subsequently edited the manuscript.

Conflict of interest statement

The authors declare that they have no competing interests.

Acknowledgments

This study was supported by Japan Society for the Promotion of Science (JSPS) KAKEN, Grant Number 18H02337.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ijpddr.2019.02.001>.

References

- Bock, R., Jackson, L., De Vos, A., Jorgensen, W., 2004. Babesiosis of cattle. *Parasitology* 129, S247–S269. <https://doi.org/10.1017/S0031182004005190>.
- Bork, S., Okamura, M., Matsui, T., Kumar, S., Yokoyama, N., Igarashi, I., 2005. Host serum modifies the drug susceptibility of *Babesia bovis* *in vitro*. *Parasitology* 130, 489–492. <https://doi.org/10.1017/S0031182004006821>.
- Brown, W.C., Norimine, J., Knowles, D.P., Goff, W.L., 2006. Immune control of *Babesia bovis* infection. *Vet. Parasitol.* 138, 75–87. <https://doi.org/10.1016/j.vetpar.2006.01.041>.
- Corey, V.C., Lukens, A.K., Istvan, E.S., Lee, M.C.S., Franco, V., Magistrado, P., Coburn-Flynn, O., Sakata-Kato, T., Fuchs, O., Gnädig, N.F., Goldgof, G., Linares, M., Gomez-Lorenzo, M.G., De Cózar, C., Lafuente-Monasterio, M.J., Prats, S., Meister, S., Tanaseichuk, O., Wree, M., Zhou, Y., Willis, P.A., Gamo, F.J., Goldberg, D.E., Fidock, D.A., Wirth, D.F., Winzeler, E.A., 2016. A broad analysis of resistance development in the malaria parasite. *Nat. Commun.* 7, 11901. <https://doi.org/10.1038/ncomms11901>.
- Everitt, J.I., Shaddock, J.A., Steinkamp, C., Clabaugh, G., 1986. Experimental *Babesia bovis* infection in Holstein calves. *Vet. Pathol.* 23, 556–562. <https://doi.org/10.1177/030098588602300503>.
- Fairlamb, A.H., Gow, N.A.R., Matthews, K.R., Waters, A.P., 2016. Drug resistance in eukaryotic microorganisms. *Nat. Microbiol.* 1, 16092. <https://doi.org/10.1038/nmicrobiol.2016.92>.
- Hwang, S.J., Yamasaki, M., Nakamura, K., Sasaki, N., Murakami, M., Wickramasekara Rajapakshage, B.K., Ohta, H., Maede, Y., Takiguchi, M., 2010. Development and characterization of a strain of *Babesia gibsoni* resistant to diminazene aceturate *in vitro*. *J. Vet. Med. Sci.* 72, 765–771. <https://doi.org/10.1292/jvms.09-0535>.
- Kellner, H.M., Eckert, H.G., Volz, M.H., 1985. Studies in cattle on the disposition of the anti-trypanosomal drug diminazene aceturate (Berenil). *Trop. Med. Parasitol.* 36, 199–204. <https://doi.org/10.1073/pnas.1202981109>.
- de Koning, H.P., Anderson, L.F., Stewart, M., Burchmore, R.J.S., Wallace, L.J.M., Barrett, M.P., 2004. The trypanocide diminazene aceturate is accumulated predominantly through the TbAT1 purine transporter: additional insights on diamidine resistance in African trypanosomes. *Antimicrob. Agents Chemother.* 48, 1515–1519. <https://doi.org/10.1128/AAC.48.5.1515-1519.2004>.
- Krause, P.J., Gewurz, B.E., Hill, D., Marty, F.M., Vannier, E., Foppa, I.M., Furman, R.R., Neuhaus, E., Skowron, G., Gupta, S., McCalla, C., Pesanti, E.L., Young, M., Heiman, D., Hsue, G., Gelfand, J.A., Wormser, G.P., Dickason, J., Bia, F.J., Hartman, B., Telford 3rd, S.R., Christianson, D., Dardick, K., Coleman, M., Giroto, J.E., Spielman,

- A., 2008. Persistent and relapsing babesiosis in immunocompromised patients. Clin. Infect. Dis. 46, 370–376. <https://doi.org/10.1086/525852>.
- Krause, P.J., Lepore, T., Sikand, V.K., Gadbaw, J., Burke, G., Telford 3rd, S.R., Brassard, P., Pearl, D., Azlanzadeh, J., Christianson, D., McGrath, D., Spielman, A., 2000. Atovaquone and azithromycin for the treatment of babesiosis. N. Engl. J. Med. 343, 1454–1458. <https://doi.org/10.1056/NEJM200011163432004>.
- Kunz, S.E., Kemp, D.H., 1994. Insecticides and acaricides: resistance and environmental impact. Rev. Sci. Tech. 13, 1249–1286. <https://doi.org/10.20506/rst.13.4.816>.
- Lemieux, J.E., Tran, A.D., Freimark, L., Schaffner, S.F., Goethert, H., Andersen, K.G., Bazner, S., Li, A., McGrath, G., Sloan, L., Vannier, E., Milner, D., Pritt, B., Rosenberg, E., Telford 3rd, S., Bailey, J.A., Sabeti, P.C., 2016. A global map of genetic diversity in *Babesia microti* reveals strong population structure and identifies variants associated with clinical relapse. Nat. Microbiol. 1, 16079. <https://doi.org/10.1038/nmicrobiol.2016.79>.
- Matsuu, A., Miyamoto, K., Ikadai, H., Okano, S., Higuchi, S., 2006. Short report: cloning of the *Babesia gibsoni* cytochrome B gene and isolation of three single nucleotide polymorphisms from parasites present after atovaquone treatment. Am. J. Trop. Med. Hyg. 74, 593–597.
- Mosqueda, J., Olvera-Ramirez, A., Aguilar-Tipacamú, G., Canto, G.J., 2012. Current advances in detection and treatment of babesiosis. Curr. Med. Chem. 19, 1504–1518. <https://doi.org/10.2174/092986712799828355>.
- Nzila, A., Mwai, L., 2010. *In vitro* selection of *Plasmodium falciparum* drug-resistant parasite lines. J. Antimicrob. Chemother. 65, 390–398. <https://doi.org/10.1093/jac/dkp449>.
- Rizk, M.A., El-Sayed, S.A., Terkawi, M.A., Youssef, M.A., El Said el Sel, S., Elsayed, G., El-Khodery, S., El-Ashker, M., Elsify, A., Omar, M., Salama, A., Yokoyama, N., Igarashi, I., 2015. Optimization of a fluorescence-based assay for large-scale drug screening against *Babesia* and *Theileria* parasites. PLoS One 10, e0125276. <https://doi.org/10.1371/journal.pone.0125276>.
- Tuvshintulga, B., Aboulaila, M., Sivakumar, T., Tayebwa, D.S., Gantuya, S., Naranbaatar, K., Ishiyama, A., Iwatsuki, M., Otoguro, K., Omura, S., Terkawi, M.A., Guswanto, A., Rizk, M.A., Yokoyama, N., Igarashi, I., 2017. Chemotherapeutic efficacies of a clonazepam and diminazene aceturate combination against piroplasm parasites and their AT-rich DNA-binding activity on *Babesia bovis*. Sci. Rep. 7, 13888. <https://doi.org/10.1038/s41598-017-14304-0>.
- Vial, H.J., Gorenflot, A., 2006. Chemotherapy against babesiosis. Vet. Parasitol. 138, 147–160. <https://doi.org/10.1016/j.vetpar.2006.01.048>.
- Witola, W.H., Tsuda, A., Inoue, N., Ohashi, K., Onuma, M., 2005. Acquired resistance to berenil in a cloned isolate of *Trypanosoma evansi* is associated with upregulation of a novel gene, TeDR40. Parasitology 131, 635–646. <https://doi.org/10.1017/S003118200500836X>.
- Wormser, G.P., Prasad, A., Neuhaus, E., Joshi, S., Nowakowski, J., Nelson, J., Mittleman, A., Aguero-Rosenfeld, M., Topal, J., Krause, P.J., 2010. Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with *Babesia microti* infection. Clin. Infect. Dis. 50, 381–386. <https://doi.org/10.1086/649859>.
- Yamasaki, M., Watanabe, N., Idaka, N., Yamamori, T., Otsuguro, K., Uchida, N., Iguchi, A., Ohta, H., Takiguchi, M., 2017. Intracellular diminazene aceturate content and adenosine incorporation in diminazene aceturate-resistant *Babesia gibsoni* isolate *in vitro*. Exp. Parasitol. 183, 92–98. <https://doi.org/10.1016/j.exppara.2017.10.016>.
- Yeruham, I., Pipano, E., Davidson, M., 1985. A field strain of *Babesia bovis* apparently resistant to amicarbalide isethionate. Trop. Anim. Health Prod. 17, 29–30.
- Yoshida, M., Reyes, S.G., Tsuda, S., Horinouchi, T., Furusawa, C., Cronin, L., 2017. Time-programmable drug dosing allows the manipulation, suppression and reversal of antibiotic drug resistance *in vitro*. Nat. Commun. 8, 15589. <https://doi.org/10.1038/ncomms15589>.